Safety of Anti-migraine Medications During Pregnancy
Author Information
Author(s): Bérard A., Strom S., Albrecht D., Kori S.
Primary Institution: Faculty of Pharmacy, University of Montreal, Montreal, Canada
Hypothesis
What is the risk of adverse pregnancy outcomes associated with the use of dihydroergotamine (DHE) or triptans during pregnancy?
Conclusion
First trimester use of DHE and triptans during pregnancy was not statistically significantly associated with increased risks for prematurity, low birth weight, major congenital malformations, or spontaneous abortion.
Supporting Evidence
- Overall, 767,994 pregnant women met eligibility criteria and were included in the analyses.
- DHE was not associated with a statistically significant risk of prematurity, low birth weight, major congenital malformations, or spontaneous abortion.
- Triptan use was not associated with any of the studied outcomes.
Takeaway
This study looked at whether certain migraine medications are safe for pregnant women. It found that using these medications in the first trimester doesn't seem to cause problems for the baby.
Methodology
A cohort study using the US Merative MarketScan Research Database from 2011 to 2021, analyzing the risks associated with DHE and triptan use during pregnancy.
Potential Biases
Potential residual confounding by indication and misclassification of spontaneous abortions.
Limitations
The study's estimates may lack statistical power due to the low prevalence of DHE and triptan use among the cohort.
Participant Demographics
Pregnant women aged 18-45 years with employer-provided health insurance in the US.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website